American Bio Medica Makes Key Additions to Sales Force; Former Roche Diagnostics Executives to Target Strategic Accounts.

Business Editors

KINDERHOOK, N.Y.--(BUSINESS WIRE)--April 16, 2001

American Bio Medica Corporation (NASDAQ: ABMC) today announced the addition of four executives to the company's sales group. Joining ABMC effective today are: Todd Bailey, Anne Becknell, James Fitzsimons, and Scott Hutton, all of whom previously held sales and/or consulting roles within Roche Diagnostics Corporation.

According to Robert L. Aromando, Jr, chief executive officer of ABMC, these new executives bring with them the insights and experiences specifically needed to help ABMC target strategic business opportunities in the onsite drugs of abuse testing market, which is growing at an estimated 23 percent annually. The addition of new sales personnel is consistent with the company's three-year business plan that focuses on multiple distribution channels to optimize top line sales.

"These are key hires for our company, and important steps forward for ABMC," said Aromando. "Bringing Todd, Anne, Jim, and Scott to ABMC strengthens an in-house sales capability that will complement and work in synergy with our important distributor strategy. The fact that these experienced professionals chose to join our team speaks volumes about our products and the culture in this company, and the fact that we brought them here should signal that we are poised to aggressively chase key large accounts."

Hutton brings with him more than 18 years in corrections and law enforcement, including the past five years in sales of onsite drugs of abuse products. He holds a Ph.D. in Criminal Justice Management from LaSalle University.

Fitzsimons retired as the Drug Program Administrator for the United States Courts in Northern California in 1995 after 30 years as a probation and parole officer. He has since served as a consultant in the criminal justice, drug testing and treatment arenas.

Becknell was a senior account manager in the drugs of abuse testing business of Roche Diagnostics for the past 10 years. She brings training, sales, and marketing experience from the criminal justice and workplace markets, and has managed several key national accounts in the retail, construction and laboratory businesses.

Bailey brings with him extensive experience selling to government, corporate headquarters, distributors, wholesalers, retailers and hospitals. He spent the past two years specializing in onsite drugs of abuse tests.

American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. ABMC's Drug Detector(TM) identifies minute traces of illegal drugs on surfaces, while the company's Rapid Drug Screen(TM) tests individuals and is proven to correlate greater than 99% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.